Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 5,000 shares of the company's stock in a transaction on Monday, May 6th. The stock was sold at an average price of $10.92, for a total value of $54,600.00. Following the sale, the director now owns 806,283 shares of the company's stock, valued at approximately $8,804,610.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Cyrus Harmon also recently made the following trade(s):
- On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.51, for a total transaction of $142,650.00.
- On Thursday, March 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.97, for a total transaction of $219,400.00.
- On Thursday, February 29th, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $12.41, for a total transaction of $310,250.00.
Olema Pharmaceuticals Price Performance
Shares of NASDAQ OLMA opened at $11.24 on Wednesday. The stock has a market capitalization of $628.65 million, a PE ratio of -5.20 and a beta of 2.10. Olema Pharmaceuticals, Inc. has a one year low of $5.02 and a one year high of $17.79. The business's fifty day moving average price is $11.44 and its 200-day moving average price is $12.84.
Missed NVDA? Buy this AI stock NOW
From Chaikin Analytics | Ad
After Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in seven months.
So if you currently own NVIDIA (NVDA)... Or were thinking of buying it in the weeks ahead...
I urge you to review my recent interview with 50-year Wall Street legend Marc Chaikin.
You can watch it here.
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its quarterly earnings data on Monday, March 11th. The company reported ($0.49) EPS for the quarter, meeting the consensus estimate of ($0.49). As a group, equities analysts expect that Olema Pharmaceuticals, Inc. will post -2.34 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms have commented on OLMA. Citigroup assumed coverage on shares of Olema Pharmaceuticals in a research report on Tuesday, January 30th. They set a "buy" rating and a $20.00 target price on the stock. Capital One Financial reissued an "overweight" rating on shares of Olema Pharmaceuticals in a research report on Thursday, February 22nd. Finally, The Goldman Sachs Group started coverage on Olema Pharmaceuticals in a research report on Tuesday, April 2nd. They set a "buy" rating and a $24.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $21.43.
Read Our Latest Stock Analysis on OLMA
Institutional Trading of Olema Pharmaceuticals
A number of institutional investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio bought a new stake in Olema Pharmaceuticals during the 3rd quarter valued at $35,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Olema Pharmaceuticals during the 4th quarter valued at $89,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Olema Pharmaceuticals in the 4th quarter worth about $130,000. SG Americas Securities LLC purchased a new position in Olema Pharmaceuticals during the 3rd quarter valued at about $142,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in shares of Olema Pharmaceuticals during the third quarter valued at about $164,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.
About Olema Pharmaceuticals
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
